Since 2013, Beth has advised biopharma companies in growth strategies, business development and licensing across a broad range of therapeutic areas and stages of development. Beth understands the key development, regulatory, commercial, financing and partnering challenges and opportunities facing Cello Health’s clients and provides creative strategies for optimising corporate, pipeline and product value in this highly complex and competitive industry.
With over 25 years’ experience in biopharma executive management and business development, culminating in her role as VP of licensing and intellectual property for Targacept, Inc., Beth drove corporate growth, pipeline advancement and partnering strategies, negotiated IPO-enabling, company-transforming billion dollar deals, managed alliances, led pre-clinical and clinical-stage projects, developed corporate communications and served as a corporate spokesperson. Beth has an impressive and industry-lauded deal sheet and has negotiated deals with global pharma that generated more than $650 million in non-dilutive upfront, milestone and R&D payments, including a $1.2 billion ($200 million cash upfront) co-development, co-promotion deal with AstraZeneca for a single Phase 3-ready depression compound, which was a finalist for Deloitte Recap’s Breakthrough Alliance of the Year in 2010. Early clinical-stage deals Beth negotiated with AstraZeneca and GlaxoSmithKline were, together, awarded the Licensing Executives Society (LES) Life Science Deal of Distinction in 2008.
Beth is a Certified Licensing Professional and a member of the Licensing Executives Society (LES). She is a graduate of High Point University.
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us